BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33812697)

  • 1. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
    Raffone A; Catena U; Travaglino A; Masciullo V; Spadola S; Della Corte L; Piermattei A; Insabato L; Zannoni GF; Scambia G; Zullo F; Bifulco G; Fanfani F; Di Spiezio Sardo A
    Gynecol Oncol; 2021 Jun; 161(3):795-801. PubMed ID: 33812697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dusp6 immunohistochemistry is associated with the response of atypical endometrial hyperplasia and early endometrial cancer to conservative treatment.
    Travaglino A; Raffone A; Gencarelli A; Micheli M; Franco L; Zullo F; Mollo A; Di Spiezio Sardo A; Bifulco G; Insabato L
    Int J Gynaecol Obstet; 2022 Sep; 158(3):742-747. PubMed ID: 34837386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Accuracy of Progesterone Receptor B in Young Women with Atypical Endometrial Hyperplasia and Early Endometrial Cancer Treated with Hysteroscopic Resection plus LNG-IUD Insertion.
    Raffone A; Travaglino A; Zullo FM; Gencarelli A; Micheli M; Miranda S; De Franciscis P; Insabato L; Di Spiezio Sardo A; Zullo F; Bifulco G
    J Minim Invasive Gynecol; 2021 Jun; 28(6):1244-1253. PubMed ID: 33122144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Predictive Factors of Response to Treatment in Patients Undergoing Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer.
    Raffone A; Travaglino A; Flacco ME; Iasevoli M; Mollo A; Guida M; Insabato L; Di Spiezio Sardo A; Carugno J; Zullo F
    J Adolesc Young Adult Oncol; 2021 Apr; 10(2):193-201. PubMed ID: 32799597
    [No Abstract]   [Full Text] [Related]  

  • 5. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
    Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
    J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical Endometrial Hyperplasia, Low-grade: "Much ADO About Nothing".
    D'Angelo E; Espinosa I; Cipriani V; Szafranska J; Barbareschi M; Prat J
    Am J Surg Pathol; 2021 Jul; 45(7):988-996. PubMed ID: 34105519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles].
    Shao WY; Dong YT; Lyu QY; Liao JB; Xue Y; Chen XJ
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):742-754. PubMed ID: 37849255
    [No Abstract]   [Full Text] [Related]  

  • 8. Endometrial Cancer Following Levonorgestrel-Releasing Intrauterine System Insertion in Young Women with Atypical Hyperplasia: Two Case Reports and Literature Review.
    Peng H; Jiang J; Li X
    Reprod Sci; 2022 Nov; 29(11):3278-3284. PubMed ID: 35641856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.
    Reijnen C; Küsters-Vandevelde HVN; Prinsen CF; Massuger LFAG; Snijders MPML; Kommoss S; Brucker SY; Kwon JS; McAlpine JN; Pijnenborg JMA
    Gynecol Oncol; 2019 Jul; 154(1):124-130. PubMed ID: 31103324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
    Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ
    Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
    Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
    Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
    Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conservative re-treatment of women with atypical endometrial hyperplasia and early endometrial carcinoma: We can hope, at least.
    Raffone A; Raimondo D; Rovero G; Travaglino A; Lopez G; Di Maio CM; Neola D; Raspollini A; Renzulli F; Filippelli A; Casadio P; Seracchioli R; Guida M
    Int J Gynaecol Obstet; 2024 May; 165(2):542-551. PubMed ID: 37772342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series.
    Zakhour M; Cohen JG; Gibson A; Walts AE; Karimian B; Baltayan A; Aoyama C; Garcia L; Dhaliwal SK; Elashoff D; Amneus M; Walsh C
    BJOG; 2017 Sep; 124(10):1576-1583. PubMed ID: 28128512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment.
    Zhou S; Xu Z; Yang B; Guan J; Shan W; Shi Y; Chen X
    J Gynecol Oncol; 2021 Jul; 32(4):e57. PubMed ID: 34085795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical efficacy and pregnancy outcomes of fertility-preserving re-treatment after recurrence of the patient with atypical endometrial hyperplasia and early stage endometrial carcinoma].
    He YJ; Wang YQ; Tang HR; He M; Rao Y; Zhou R; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2020 Jan; 55(1):21-28. PubMed ID: 32074769
    [No Abstract]   [Full Text] [Related]  

  • 17. Hysteroscopic morphological pattern reflects histological grade of endometrial cancer.
    Miyamoto T; Abiko K; Murakami R; Furutake Y; Baba T; Horie A; Hamanishi J; Mandai M
    J Obstet Gynaecol Res; 2019 Aug; 45(8):1479-1487. PubMed ID: 31074203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of morular metaplasia in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial carcinoma patients.
    Wu P; Lv Q; Guan J; Shan W; Chen X; Zhu Q; Luo X
    Arch Gynecol Obstet; 2022 Oct; 306(4):1135-1146. PubMed ID: 35246715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of coexisting endometrial carcinoma in case of atypical endometrial hyperplasia diagnosed on total hysteroscopic resection.
    Pivano A; Crochet P; Carcopino X; Cravello L; Boubli L; Agostini A
    Eur J Obstet Gynecol Reprod Biol; 2016 Aug; 203():210-3. PubMed ID: 27343737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fertility-sparing treatment for endometrial cancer and atypical endometrial hyperplasia in patients with Lynch Syndrome: Molecular diagnosis after immunohistochemistry of MMR proteins.
    Catena U; Della Corte L; Raffone A; Travaglino A; Lucci Cordisco E; Teodorico E; Masciullo V; Bifulco G; Di Spiezio Sardo A; Scambia G; Fanfani F
    Front Med (Lausanne); 2022; 9():948509. PubMed ID: 36091691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.